and fertility-sparing surgery (p=0.001) but not with the tumor histology (p=0.215).

**Conclusion** The study delineated two different patient profiles related to the tumor pattern of growth. The exophytic pattern was associated with the presence of invasive and non-invasive peritoneal implants, an advanced FIGO stage, without impact on DFS. Identification of the BOT pattern during preoperative workup could be useful for better surgical planning.

**2022-RA-1527-ESGO** RELIABILITY OF IOTA ADNEX MODEL IN BORDERLINE OVARIAN TUMORS, A SINGLE CENTER STUDY

1Humaira Aziz, 2Rozila Sadia Khan, 3Gulnaz Shafigat, 4Aliya Begum Aziz. 1Gynaec-Oncology, Aga Khan University Hospital Karachi Pakistan, karachi, Pakistan; 2Obstetrics and Gynaecology, Aga Khan University Hospital, Karachi, Pakistan; 3Department of Radiology, Aga Khan University Hospital, Karachi, Pakistan

10.1136/ijgc-2022-ESGO.737

**Introduction/Background** The discrimination of borderline ovarian tumor (BOT) is challenging Ultrasonography (US) is the most essential imaging modality for distinguishing ovarian masses but depends on the experience of radiologists. In 2014, the IOTA group carried out the assessment of different neoplasia’s in the Adnex Model. It was used to discriminate benign, BOTs, stage I, stage II-IV invasive ovarian cancer, and secondary metastatic cancer. This study aims to evaluate the efficacy of the Adnex model in the determination of BOTs.

**Methodology** This was a retrospective study, medical records of histopathologically proven cases of BOTs were included from the year 2009 to 2021. The ultrasound and clinical findings were entered in an online Adnex calculator. These results were used to calculate the absolute risk predicting the probability of mass being as BOT.

**Results** A total of 22 cases of BOT were included. Efficacy in terms of sensitivity of the Adnex model for preoperative diagnosis of BOTs was 18.2% [95%CI: 7.31–38.52]. Performance of the Adnex model based on absolute risk (AR) improves with a selection of a more inclusive cut-off value, varying from 4.5% (1/22) correctly classified case of BOT with the cut-off 20%,18.2% (4/22) with the cut-off 10% and up to 55.5% (12/22) classified cases of BOT with cut off value of 3%. Similarly, relative risk (RR) was also used to classify the BOT, but only 4(18.2%) cases were identified correctly.

**Conclusion** More encompassing cut-off values allow the model to differentiate BOTs better. The calculation based on RR or AR with a cut-off value of at least 10% should be used when evaluating BOTs. The IOTA Adnex model did not perform well in predicting cases of BOTs that were histopathologically proven in terms of sensitivity.

**2022-RA-15140-ESGO** MITO 25.1: A RANDOMIZED, MOLECULAR DRIVEN PHASE II TRIAL OF CARBOPLATIN-PACLITAXEL-BEVACIZUMAB VS CARBOPLATIN-PACLITAXEL-BEVACIZUMAB-RUCAPARIB VS CARBOPLATIN-PACLITAXEL-BEVACIZUMAB-RUCAPARIB, SELECTED ACCORDING TO HRD STATUS, IN PATIENTS WITH ADVANCED (STAGE III B-C-IV) OVARIAN, PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCER

1Lucia Musacchio, 2Vanda Salutari, 3Sandro Pignata, 4Giorgio Valabrega, 5Laura Zavallone, 6Gennaro Corino, 7Anna Maria Mosconi, 8Serena Giolitto, 9Elena Giudice, 10Caterina Ricci, 11Caudio Zamegni, 12Camilla Nero, 13Maria Vittoria Carbono, 14Viola Ghizzoni, 15Roberto Soric, 16Salvatore Siena, 17Francesca Tronconi, 18Antonella Savarese, 19Giovanni Scambia, 20Domenica Lorusso, 21Patrizia Rosso, 22Luca Sant, 23Marche Polytechnic University, Ancona, Italy; 24Ospedale Niguarda Milano, Milan, Italy; 25Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy; 26Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy; 27Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy; 28Istituto di Candiolo, IRCCS, Turin, Turin, Italy; 29Departmental Medical Oncology, Infermi Hospital, Billia, Italy; 30Interdisciplinary Department of Medicine, Bari, Italy; 31Medical Oncology, Ospedale S. Maria della Misericordia, Perugia, Italy; 32Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy; 33Pollicino Sant’Orsola Malpighi, Policlinico Sant’Orsola Malpighi, Italy; 34Fondazione Policlinico A Gemelli IRCCS, Rome, Italy; 35CRC Aviano, Aviano, Italy; 36Ospedale Niguarda Milanino, Milan, Italy; 37Marche Polytechnic University, Ancona, Italy; 38Istituto Nazionale dei Tumori Regina Elena, IFO, Rome, Italy

10.1136/ijgc-2022-ESGO.739

**Introduction/Background** Poly (ADP-ribose) polymerase (PARP) inhibitors alone and in combination with Bevacizumab have shown significant clinical benefit as maintenance therapy in ovarian carcinoïd tumours of the ovary. The efficacy of the Adnex model in the determination of BOTs.

**Methodology** Five patients diagnosed of ovarian carcinoïd at Hospital Santa Cristina in Madrid, Spain are included. Four patients were diagnosed of primary ovarian carcinoïd tumor and one patient was diagnosed of ovarian metastases of an appendicular carcinoïd tumor.

**Results** 2 patients were premenopausal and presented unilateral mass suspicious of teratoma, so they underwent unilateral adnexectomy, with postoperative diagnosis of ovarian carcinoïd tumor stage IA. Long-term follow-up, 10 years after treatment, both patients required adnexectomy, with no presence of disease recurrence. 2 patients were postmenopausal. The first had an ovarian mass that suggested teratoma, so she underwent bilateral adnexectomy plus hysterectomy; postoperatively she presented heart carcinoid syndrome, and required surgical correction. The second patient had suspicion for peritoneal carcinomatosis, so she underwent complete cytoreductive surgery. Both were stage IA. The fifth patient had an ovarian recurrence of an appendicular carcinoïd. All patients diagnosed of primary ovarian carcinoïd were free of disease when data were collected.

**Conclusion** Ovarian carcinoïds represent a rare entity that requires surgery and is often diagnosed postoperatively. Prognosis is excellent when diagnosed at early-stage, but survival is low if carcinoïd tumor is advanced-stage or metastases from a non-ovarian origin. Late relapses are possible.